---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-008748"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T14:23:20.828410+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharma reports no brain toxicity in FDA-required Ketamir-2 study

## Summary
- Ketamir-2 showed no mortality, adverse signs, or brain lesions in rats at high doses.
- Positive control MK-801 caused vacuolation and neuronal necrosis (Olney lesions).
- Results to be submitted to FDA as part of ongoing regulatory communications.
- Study supports Ketamir-2's safety profile versus ketamine-linked neurotoxicity.

## SEC filing metadata
- accession: 0001641172-25-008748
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225008748/0001641172-25-008748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225008748/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-008748
- JSON: https://secwatch.observer/filing/0001641172-25-008748.json
- Plain text: https://secwatch.observer/filing/0001641172-25-008748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.